Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Natalizumab in multiple sclerosis: proceed with caution?

Doggrell SA.

Expert Opin Pharmacother. 2006 Aug;7(12):1675-8.

PMID:
16872271
2.

[Natalizumab in the treatment of multiple sclerosis].

Horga A, Horga de la Parte JF.

Rev Neurol. 2007 Sep 1-15;45(5):293-303. Review. Spanish.

3.

Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.

Johnson KP.

Neurologist. 2007 Jul;13(4):182-7. Review.

PMID:
17622909
4.

[Blocking adhesion molecules with natalizumab in multiple sclerosis].

Schreiner B, Kieseier BC, Hartung HP, Hohlfeld R, Wiendl H.

Nervenarzt. 2005 Aug;76(8):999-1005. Review. German.

PMID:
15812675
5.
6.

Natalizumab: new drug. Multiple sclerosis: risky market approval.

[No authors listed]

Prescrire Int. 2008 Feb;17(93):7-10.

PMID:
18354844
7.

Natalizumab update.

Sweet BV.

Am J Health Syst Pharm. 2007 Apr 1;64(7):705-16. Review.

PMID:
17384355
8.

Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis.

O'Connor P.

Expert Opin Biol Ther. 2007 Jan;7(1):123-36. Review.

PMID:
17150024
9.

Natalizumab for the treatment of multiple sclerosis and Crohn's disease.

Keeley KA, Rivey MP, Allington DR.

Ann Pharmacother. 2005 Nov;39(11):1833-43. Epub 2005 Oct 11. Review.

PMID:
16219898
10.

Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology..

Neurology. 2008 Sep 2;71(10):766-73. doi: 10.1212/01.wnl.0000320512.21919.d2. Review.

PMID:
18765653
11.

Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.

Langer-Gould A, Steinman L.

Curr Neurol Neurosci Rep. 2006 May;6(3):253-8. Review.

PMID:
16635435
12.

The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications.

Sheremata WA, Minagar A, Alexander JS, Vollmer T.

CNS Drugs. 2005;19(11):909-22. Review.

PMID:
16268663
13.

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators..

J Neurol. 2009 Mar;256(3):405-15. doi: 10.1007/s00415-009-0093-1. Epub 2009 Mar 18. Erratum in: J Neurol. 2009 Jun;256(6):1035-7.

PMID:
19308305
14.

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.

O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N.

Neurology. 2011 May 31;76(22):1858-65. doi: 10.1212/WNL.0b013e31821e7c8a. Epub 2011 May 4.

PMID:
21543733
15.

The effects of natalizumab on the innate and adaptive immune system in the central nervous system.

Stüve O.

J Neurol Sci. 2008 Nov 15;274(1-2):39-41. doi: 10.1016/j.jns.2008.03.022. Epub 2008 May 12. Review.

PMID:
18474372
16.

Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.

Ko HH, Bressler B.

Expert Rev Gastroenterol Hepatol. 2007 Oct;1(1):29-39. doi: 10.1586/17474124.1.1.29. Review.

PMID:
19072431
17.
18.

alpha4-Integrin antagonism with natalizumab: effects and adverse effects.

Stüve O, Gold R, Chan A, Mix E, Zettl U, Kieseier BC.

J Neurol. 2008 Dec;255 Suppl 6:58-65. doi: 10.1007/s00415-008-6011-0. Review.

PMID:
19300961
19.

Review of progressive multifocal leukoencephalopathy and natalizumab.

Aksamit AJ.

Neurologist. 2006 Nov;12(6):293-8. Review.

PMID:
17122725
20.

Natalizumab: targeting alpha4-integrins in multiple sclerosis.

Engelhardt B, Kappos L.

Neurodegener Dis. 2008;5(1):16-22. Review.

PMID:
18075270

Supplemental Content

Support Center